Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620254 · ClinicalTrials.gov registry record
Mast Cell Connect: A Registry for Patients With Mastocytosis
A clinical trial, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- 743
- Enrollment target
NCT02620254: Completed study, sponsored by Blueprint Medicines Corporation.
NCT02620254 is a clinical trial that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 743 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02620254 has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- 743 participants
- Enrollment target
Study Summary
The Mast Cell Connect Registry is a voluntary, observational database that will capture demographic, socioeconomic, and disease information directly from patients with mastocytosis via a secure web-based tool. No experimental intervention is involved.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 743 participants |
| Start Date | 2015-11 |
| Est. Completion | 2021-01 |
What the finished NCT02620254 record still lists
NCT02620254 is an observational study that tracks outcomes without assigning an intervention. The registered 743 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02620254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02620254 about?
NCT02620254 is a clinical study titled "Mast Cell Connect: A Registry for Patients With Mastocytosis". The Mast Cell Connect Registry is a voluntary, observational database that will capture demographic, socioeconomic, and disease information directly from patients with mastocytosis via a secure web-based tool. No experimental intervention is involved.
What is the current status of trial NCT02620254?
This trial is currently completed. The enrollment target is 743 participants. The study started on 2015-11. Estimated completion is 2021-01.
Who is sponsoring clinical trial NCT02620254?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia